8037 — China Biotech Services Holdings Balance Sheet
0.000.00%
- HK$936.70m
 - HK$1.11bn
 - HK$70.51m
 
Annual balance sheet for China Biotech Services Holdings, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2020 December 31st  | 2021 December 31st  | 2022 December 31st  | 2023 December 31st  | 2024 December 31st  | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — | 
| Source: | ARS | ARS | ARS | ARS | ARS | 
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS | 
| Status: | Final | Final | Final | Final | Final | 
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 386 | 152 | 92.8 | 72.1 | 18.9 | 
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 46.2 | 108 | 761 | 45 | 25.5 | 
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 446 | 278 | 885 | 261 | 63.1 | 
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 148 | 105 | 129 | 124 | 235 | 
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 904 | 707 | 1,470 | 662 | 530 | 
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 272 | 227 | 549 | 159 | 193 | 
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 561 | 311 | 868 | 200 | 265 | 
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 343 | 395 | 603 | 463 | 265 | 
| Total Liabilities & Shareholders' Equity | 904 | 707 | 1,470 | 662 | 530 | 
| Total Common Shares Outstanding |